Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients
Kidney Int Rep
.
2022 Dec;7(12):2718-2721.
doi: 10.1016/j.ekir.2022.09.005.
Epub 2022 Sep 11.
Authors
Daisuke Kanai
1
,
Hiromichi Wakui
1
,
Tatsuya Haze
2
,
Kengo Azushima
1
,
Sho Kinguchi
1
,
Tomohiko Kanaoka
1
,
Yoshiyuki Toya
1
,
Nobuhito Hirawa
3
,
Hideaki Kato
4
,
Kazushi Uneda
5
,
Fumimasa Watanabe
6
,
Kanako Hanaoka
6
,
Masaaki Hanaoka
6
,
Hiroshi Mitsuhashi
6
,
Satoshi Yamaguchi
7
,
Toshimasa Ohnishi
6
,
Kouichi Tamura
1
Affiliations
1
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
2
Center for Nobel and Exploratory Clinical Trials (Y-NEXT), Yokohama City University, Yokohama, Japan.
3
Department of Nephrology and Hypertension, Yokohama City University Medical Center, Yokohama, Japan.
4
Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan.
5
Department of Kampo Medicine, Aizu Medical Center, Fukushima Medical University School of Medicine, Aizuwakamatsu, Japan.
6
Kohsaikai Kamioooka Jinsei Clinic, Yokohama, Japan.
7
Kohsaikai Yokohama Jinsei Hospital, Yokohama, Japan.
PMID:
36120389
PMCID:
PMC9464310
DOI:
10.1016/j.ekir.2022.09.005
No abstract available
Keywords:
BNT162b2; antibody; dialysis; spike protein SARS-CoV-2; vaccine.